At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
3-phthalimidoglutarimide (Thalidomide)drug
Likely dose
3-phthalimidoglutarimide (Thalidomide) 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Refractory Epilepsy With Thalidomide: an Open Trial
National Institute of Neurology and Neurosurgery, Mexico·interventional·Posted Feb 3, 2010·Updated Feb 18, 2010
In Brief
A Phase 2 clinical trial evaluating 3-phthalimidoglutarimide (Thalidomide) for Refractory Epilepsy. Completed, enrolled 7 participants.
Detailed Summary
The purpose of this study is to determine whether thalidomide is effective in the refractory epilepsy treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Epilepsy
Countries--
CollaboratorsNational Council of Science and Technology, Mexico
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
Primary CompletionJun 2007
Study CompletionJan 2008
First PostedFeb 2010
TodayJul 2026
First PostedFeb 3, 2010
Enrollment StartJun 1, 2006
Primary CompletionJun 1, 2007
Study CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.4 years ago
Interventions
3-phthalimidoglutarimide (Thalidomide)drug
Thalidomide at 200 mg dosage bid was administered during a twelve month period.